NeuroOne Medical Technologies Corp 2025年度报告

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatement that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ As of March 31, 2025, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate marketvalue of shares of the registrant’s common stock held by non-affiliates of the registrant based upon the March 31, 2025 price at which EXPLANATORY NOTE NeuroOne Medical Technologies Corporation (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to itsAnnual Report on Form 10-K for the year ended September 30, 2025, as filed on December 17, 2025 (the “Original Form 10-K”) withthe Securities and Exchange Commission (the “SEC”), solely to provide the Part III information of Form 10-K that was to beincorporated by reference from the Company’s definitive proxy statement for its 2026 Annual Meeting of Stockholders (the “Proxy In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by ourprincipal executive officer and principal financial officer are filed as Exhibits 31.1 and 31.2 to this Amendment under Item 15 of PartIV hereof. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any Except as described above, no other changes have been made to the Original Form 10-K, and this Amendment does notamend, update or change any other items or disclosures in the Original Form 10-K. The Original Form 10-K continues to speak as ofits original filing date. This Amendment does not reflect subsequent events occurring after the filing date of the Original Form 10-K or PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Directors and Executive Officers The Board of Directors of the Company (the “Board”) is divided into three classes. Members of each class serve staggered three-yearterms. The following table provides information as to each person who is, as of the filing hereof, a director and/or executive officer ofthe Company: No Family Relationships There is no family relationship between any director and executive officer or among any directors or executive officers. Business Experience and Background of Directors and Executive Officers David Rosa Mr. Rosa has served as the Chief Executive Officer, President and a director of the Company since July 2017 and served as chiefexecutive officer and a director of NeuroOne, Inc., formerly our wholly-owned subsidiary, from October 2016 until December 2019,when NeuroOne, Inc. merged with and into the Company. From November 2009 to November 2015, Mr. Rosa served as the chiefexecutive officer and president of Sunshine Heart, Inc., n/k/a Nuwellis, Inc. (Nasdaq: NUWE), a publicly-held early-stage medical From 2004 to 2008, Mr. Rosa served as the vice president of global marketing for cardiac surgery and cardiology at St. Jude Medical